182 related articles for article (PubMed ID: 11706393)
1. The role of HER2 in angiogenesis.
Kumar R; Yarmand-Bagheri R
Semin Oncol; 2001 Oct; 28(5 Suppl 16):27-32. PubMed ID: 11706393
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis.
Bagheri-Yarmand R; Vadlamudi RK; Wang RA; Mendelsohn J; Kumar R
J Biol Chem; 2000 Dec; 275(50):39451-7. PubMed ID: 10967114
[TBL] [Abstract][Full Text] [Related]
4. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.
Yen L; Benlimame N; Nie ZR; Xiao D; Wang T; Al Moustafa AE; Esumi H; Milanini J; Hynes NE; Pages G; Alaoui-Jamali MA
Mol Biol Cell; 2002 Nov; 13(11):4029-44. PubMed ID: 12429844
[TBL] [Abstract][Full Text] [Related]
6. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
[TBL] [Abstract][Full Text] [Related]
7. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Laughner E; Taghavi P; Chiles K; Mahon PC; Semenza GL
Mol Cell Biol; 2001 Jun; 21(12):3995-4004. PubMed ID: 11359907
[TBL] [Abstract][Full Text] [Related]
8. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
Pegram MD; Reese DM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):29-37. PubMed ID: 12138395
[TBL] [Abstract][Full Text] [Related]
9. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
[TBL] [Abstract][Full Text] [Related]
10. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
11. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
[TBL] [Abstract][Full Text] [Related]
12. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
13. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer.
Li G; Zheng J; Xu B; Ling J; Qiu W; Wang Y
Biomed Pharmacother; 2017 Jan; 85():418-424. PubMed ID: 27887848
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY
Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515
[TBL] [Abstract][Full Text] [Related]
16. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.
Price DJ; Miralem T; Jiang S; Steinberg R; Avraham H
Cell Growth Differ; 2001 Mar; 12(3):129-35. PubMed ID: 11306513
[TBL] [Abstract][Full Text] [Related]
17. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P
Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311
[TBL] [Abstract][Full Text] [Related]
18. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Rosen LS
Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
